Everolimus

Last Updated: 02/24/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9261 publications

mTORC1 inhibitors rapamycin and everolimus as host-directed therapy for tuberculosis.

mTORC1 inhibitors rapamycin and everolimus as host-directed therapy for tuberculosis.

Journal: Infection and immunity
Published: January 21, 2026

The combination of BCL-xL PROTAC and mTOR inhibitor sensitizes pancreatic ductal adenocarcinoma to KRAS G12D inhibitor treatment by enhancing apoptosis induction.

The combination of BCL-xL PROTAC and mTOR inhibitor sensitizes pancreatic ductal adenocarcinoma to KRAS G12D inhibitor treatment by enhancing apoptosis induction.

Journal: bioRxiv : the preprint server for biology
Published: January 16, 2026

BNIP3-mTOR Signaling Mediates Resistance to MET Inhibition in Glioblastoma.

BNIP3-mTOR Signaling Mediates Resistance to MET Inhibition in Glioblastoma.

Journal: bioRxiv : the preprint server for biology
Published: January 08, 2026

Computer prediction and genetic analysis identifies retinoic acid modulation as a driver of conserved longevity pathways in genetically diverse Caenorhabditis nematodes.

Computer prediction and genetic analysis identifies retinoic acid modulation as a driver of conserved longevity pathways in genetically diverse Caenorhabditis nematodes.

Journal: eLife
Published: December 23, 2025

Marked Reduction in Tacrolimus and Everolimus Blood Levels Associated With Sotorasib: A Critical Drug Interaction in a Kidney Transplant Recipient.

Marked Reduction in Tacrolimus and Everolimus Blood Levels Associated With Sotorasib: A Critical Drug Interaction in a Kidney Transplant Recipient.

Journal: Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
Published: December 18, 2025

Agreement between health care claims and the physician's follow-up visits in the determination of post-transplant immunosuppressive therapies: the CESIT study

Agreement between health care claims and the physician's follow-up visits in the determination of post-transplant immunosuppressive therapies: the CESIT study

Journal: Epidemiologia e prevenzione
Published: December 16, 2025

Rectal neuroendocrine tumor (G1) with widespread metastasis 8 years after endoscopic resection.

Rectal neuroendocrine tumor (G1) with widespread metastasis 8 years after endoscopic resection.

Journal: Fukushima journal of medical science
Published: December 14, 2025

Effect of Probiotics on Immunosuppressive Drug Pharmacokinetics: Interaction between Bacillus subtilis and Tacrolimus in Mice.

Effect of Probiotics on Immunosuppressive Drug Pharmacokinetics: Interaction between Bacillus subtilis and Tacrolimus in Mice.

Journal: Biological & pharmaceutical bulletin
Published: December 14, 2025

Renal Function Outcomes in Tuberous Sclerosis Complex Patients Receiving Everolimus for Renal Angiomyolipoma.

Renal Function Outcomes in Tuberous Sclerosis Complex Patients Receiving Everolimus for Renal Angiomyolipoma.

Journal: European urology open science
Published: December 13, 2025

In silico Deployment Modeling of an Everolimus Coated Balloon.

In silico Deployment Modeling of an Everolimus Coated Balloon.

Journal: Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference
Published: December 03, 2025

Chromogranin A-Associated Tubulopathy in a Patient With Neuroendocrine Tumor.

Chromogranin A-Associated Tubulopathy in a Patient With Neuroendocrine Tumor.

Journal: Cureus
Published: December 03, 2025

Surface-engineered dual drug-loaded tumor-targeted liposomal nanoparticles to overcome the therapeutic resistance in glioblastoma multiforme.

Surface-engineered dual drug-loaded tumor-targeted liposomal nanoparticles to overcome the therapeutic resistance in glioblastoma multiforme.

Journal: Research square
Published: November 24, 2025
Showing 1-12 of 9,261

Last Updated: 02/24/2026